Physician profile
Thomas H Cahn
NPI 1306828843
$2,765.48
in general payments reported to CMS, 2019-2025
15 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.69 · 2022: $81.80 · 2023: $380 · 2024: $918 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $635.91 | 2025 | Klisyri |
| Abbvie INC. | $388.36 | 2023-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $361.40 | 2024-2025 | Bimzelx |
| Incyte Corporation | $271.54 | 2022-2025 | Opzelura, Opzelura |
| Amgen INC. | $268.24 | 2024-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $242.41 | 2019-2025 | |
| Pfizer INC. | $170.10 | 2023-2025 | |
| Genzyme Corporation | $89.98 | 2023-2025 | |
| Leo Pharma INC. | $70.51 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $67.09 | 2024 | Sotyktu |
| Biofrontera INC. | $66.19 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Sun Pharmaceutical Industries INC. | $48.78 | 2022-2023 | Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $39.95 | 2024 | Dupixent |
| Journey Medical Corporation | $24.43 | 2023 | |
| Janssen Biotech, INC. | $20.59 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.